Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 0.0x - 0.0x | 0.0x |
| Historical Pb Multiple | -3.6x - 10.7x | -0.1x |
| Fair Value | $0.00026 - $0.00029 | $0.00027 |
| Upside | -48.0% - -42.5% | -45.3% |
| Benchmarks | - | Full Ticker |
| 4Front Ventures Corp. | - | OTCPK:FFNT.F |
| Harmony Biosciences Holdings, Inc. | - | NasdaqGM:HRMY |
| Evolus, Inc. | - | NasdaqGM:EOLS |
| Tarsus Pharmaceuticals, Inc. | - | NasdaqGS:TARS |
| Bio Essence Corporation | - | OTCPK:BIOE |
| CNBX Pharmaceuticals Inc. | - | OTCPK:CNBX |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| FFNT.F | HRMY | EOLS | TARS | BIOE | CNBX | |||
| OTCPK:FFNT.F | NasdaqGM:HRMY | NasdaqGM:EOLS | NasdaqGS:TARS | OTCPK:BIOE | OTCPK:CNBX | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | 61.4% | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 31.3% | 57.3% | -16.5% | 38.7% | -215.1% | 81.4% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -170.4% | 15.2% | -76.7% | -249.9% | -179.4% | -29427.1% | ||
| Prior Fiscal Year | -19.8% | 22.1% | -30.5% | -778.9% | NA | -904.6% | ||
| Latest Fiscal Year | -45.9% | 20.4% | -18.9% | -63.2% | -483.3% | -534.5% | ||
| Latest Twelve Months | -46.6% | 23.4% | -22.3% | -31.1% | -243.6% | NA | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -237.0% | 15.8% | -478.9% | -38.3% | NA | -279.5% | ||
| Prior Fiscal Year | -64.9% | 29.6% | -666.9% | -69.7% | NM | NM | ||
| Latest Twelve Months | NM | 27.6% | -642.0% | -31.5% | NM | NM | ||
| Next Fiscal Year | 82.7% | 32.5% | 289.2% | -31.6% | #NUM! | #NUM! | ||
| Two Fiscal Years Forward | -190.2% | 34.8% | -42.5% | 20.4% | 96.0% | 24.6% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 0.0x | 2.8x | 1.8x | 8.4x | 8.1x | NA | ||
| Price / LTM EPS | -0.1x | 11.8x | -8.0x | -27.0x | -3.3x | -0.6x | ||
| Price / Book | -0.1x | 2.8x | -26.5x | 7.5x | -1.5x | -0.1x | ||
| Price / Fwd Book | 0.0x | 2.4x | -17.6x | 15.2x | -1.5x | -0.1x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -26.5x | -0.1x | 7.5x | |||||
| Historical P/B Ratio | -3.6x | -0.1x | 10.7x | |||||
| Selected P/B Multiple | 0.0x | 0.0x | 0.0x | |||||
| (x) Book Value | (3) | (3) | (3) | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | FFNT.F | HRMY | EOLS | TARS | BIOE | CNBX | |
| Value of Common Equity | 0 | 2,138 | 495 | 2,484 | 5 | 0 | |
| (/) Shares Outstanding | 916.4 | 57.5 | 64.7 | 42.2 | 38.0 | 352.2 | |
| Implied Stock Price | 0.00 | 37.17 | 7.65 | 58.85 | 0.12 | 0.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.00 | 37.17 | 7.65 | 58.85 | 0.12 | 0.00 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |